From Insight to Impact
Advancing clinical trials through RWE in Asia-Pacific
Prasanthi Sadhu, Editor, Pharma Focus Asia
Asia-Pacific is shaping a new era in clinical development. As healthcare systems across the region confront rising disease burdens, ageing populations, and growing cost pressures, pharmaceutical companies are being challenged to deliver not only innovation, but demonstrable value. In this context, real-world evidence (RWE) has evolved from a supportive data stream into a strategic cornerstone of evidence generation.
Although randomised controlled trials remain the benchmark for regulatory approval, they do not always capture the full spectrum of patient diversity and clinical realities across Asia-Pacific’s heterogeneous healthcare systems. The region spans highly digitised, research-intensive markets as well as emerging ecosystems still building infrastructure and capacity. As a result, stakeholders increasingly require evidence that is not only scientifically robust but also contextually relevant. Real-world data—drawn from electronic health records, insurance claims, patient registries, and digital health technologies—plays a critical role in closing this gap by revealing how therapies perform in routine clinical practice.
For industry leaders, RWE is now embedded earlier in the development continuum. It guides more informed protocol design, enhances recruitment strategies, refines endpoint selection, and strengthens market access positioning. At the same time, hybrid and decentralised trial approaches are expanding, improving reach across geographically dispersed and diverse populations while streamlining operations. In a region as expansive and demographically varied as Asia-Pacific, these flexible models offer practical solutions to the logistical and representational challenges of traditional trial frameworks.
Regulators and health technology assessment bodies across the region are also expanding their openness to RWE. Real-world insights are being used to support post-market surveillance, label expansions, and reimbursement decisions, especially as payers demand evidence of long-term effectiveness and cost efficiency. In value-driven healthcare systems, demonstrating outcomes in routine practice can be a powerful differentiator.
However, transforming data into meaningful impact requires overcoming persistent challenges. Data fragmentation, diverse standards, and varied governance frameworks across markets can limit interoperability and comparability. Maintaining methodological rigor and ensuring transparency in analytics are essential to building trust with regulators, payers, and healthcare providers.
Collaboration will be critical to advancing this transformation. Investments in digital infrastructure, cross-sector partnerships, and regional data networks are strengthening the evidence ecosystem. Advanced analytics and artificial intelligence are further enhancing the ability to derive actionable insights from complex datasets.
For B2B stakeholders across pharma, biotech, CROs, and technology providers, the mandate is clear: embed RWE into a unified clinical and commercial strategy. Those who successfully translate real-world insights into measurable outcomes will not only accelerate development timelines but also reinforce value propositions in increasingly outcome-focused markets.
“From Real World to Real Impact” captures this pivotal shift. In Asia-Pacific, the future of clinical research will be defined not only by controlled trials, but by how effectively real-world insights are harnessed to deliver tangible improvements in patient care.
This issue also covers our Experts' Perspectives in section ‘Pharma Pulse ‘ by Dr Deepak Mukherjee, Director - Clinical, Medical, Regulatory, Quality (CMRQ), Novo Nordisk; Kavita Lamror, Partner, RWE & Digital Transformation, MAXIS CLINICAL SCIENCES and Yun Lu - VP & Chief Science and Innovation Officer, Navitas Life Sciences talking about From Real World to Real Impact - Transforming Trials in the Era of RWE in Asia-Pacific.
Author Bio
Prasanthi Sadhu, Editor, Pharma Focus Asia
